Previous 10 | Next 10 |
Exelixis (EXEL) announces that, effective immediately, Gisela Schwab, the company's president, product development and medical affairs and CMO, has begun a medical leave of absence.Schwab will remain available to advise Exelixis as needed during her leave."During her leave, the highly ta...
Exelixis, Inc. (Nasdaq: EXEL) announced that, effective today, Gisela M. Schwab, M.D., the company’s President, Product Development and Medical Affairs and Chief Medical Officer, has begun a medical leave of absence. Dr. Schwab will remain available to advise Exelixis as need...
phototechno/iStock via Getty Images Calling Exelixis (EXEL) "a powerhouse of clinical and commercial excellence," H.C. Wainwright analyst Michael King is initiating shares of the biotech with a buy rating and a $47 price target (upside of ~107%). Analyst Michael King highlighted the company's...
– Expansion cohorts to include patients with advanced kidney, prostate and bladder cancers – Exelixis, Inc. (Nasdaq: EXEL) today announced a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Company (NYSE: BMY) for STELLAR-002,...
– New findings demonstrate the significant progression-free survival benefit seen in the intent-to-treat population was also consistent across subgroups – – Results from COSMIC-311 served as basis for Exelixis’ recent supplemental New Drug App...
Exelixis (NASDAQ: EXEL) continues to grow sales of its cancer drug Cabometyx, thanks in large part to data showing the drug works well in combination with Bristol Myers Squibb 's (NYSE: BMY) Opdivo. In this video from Motley Fool Live , recorded on May 10 , ...
– Patients treated with CABOMETYX in combination with OPDIVO had significantly longer total time without symptoms or toxicity – – Data to be presented during the 2021 American Society of Clinical Oncology’s Annual Meeting – ...
– Efficacy benefits with recently approved combination regimen observed regardless of baseline International Metastatic Renal Cell Carcinoma Database Consortium risk status, organ site of metastases or extent of tumor burden – – Data to be presented ...
– CABOMETYX in combination with OPDIVO demonstrated an objective response rate of 47.5% in a cohort of patients with certain histologies of advanced or metastatic nccRCC – – Data to be presented during the 2021 American Society of Clinical Oncology...
Exelixis ([[EXEL]] -3.2%) is trading ~3.1% lower in the post-market after announcing results from the metastatic castration-resistant prostate cancer ((CRPC)) cohort six of the COSMIC-021 study for cabozantinib (CABOMETYX) and atezolizumab combination in locally advanced/ metastatic soli...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...